Clinical Trials in New York State

Showing 1701-1720 of 14,718 trials

Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

NCT04652570

This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary MN

Membranous Nephropathy

Tenet Medicines6 participantsStarted May 2021

Los Angeles, California, United States • Albany, New York, United States • Bethlehem, Pennsylvania, United States +1 more locations

Active Not RecruitingPhase 377 miles

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04162210

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered on Day 1 (D1) at every 3 weeks (Q3W) schedule. Pomalidomide will be administered daily on Days 1 to 21 of each 28-day cycle, with dexamethasone administered once weekly (Days 1, 8, 15, and 22). Participants in both arms will be treated until disease progression, death, unacceptable toxicity, withdrawal of consent, and lost to follow-up or end of study, whichever comes first.

Multiple Myeloma

GlaxoSmithKline325 participantsStarted Mar 2021

Tucson, Arizona, United States • Pueblo, Colorado, United States • Detroit, Michigan, United States +99 more locations

Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Find Trials by Condition in New York State

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

Siplizumab in T1DM

Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment